School of Medicine

Showing 201-220 of 235 Results

  • Branden Tarlow

    Branden Tarlow

    Postdoctoral Medical Fellow, Gastroenterology
    Fellow in Medicine

    Current Research and Scholarly InterestsPhysician scientist interested in liver regeneration, cell therapy, and cancer

  • Robert Thibault

    Robert Thibault

    Postdoctoral Scholar, SCRDP/ Heart Disease Prevention

    BioDr. Thibault studies how to increase the rigour and reproducibility of scientific research. His work focuses on developing and evaluating solutions to shortcomings in the research ecosystem. He completed a PhD in cognitive neuroscience at McGill University in 2019. His doctoral work focused on brain imaging, including neurofeedback, placebos, and suggestion. This work is outlined in his book, Casting Light on The Dark Side of Brain Imaging, co-editied with Dr. Amir Raz. He then worked as a postdoctoral researcher at the University of Bristol University before joining the Meta-Research Innovation Center at Stanford University (METRICS) in 2021. His publications are available at

  • Laurens van de Wiel

    Laurens van de Wiel

    Postdoctoral Scholar, Cardiovascular Medicine

    BioLaurens van de Wiel is Dutch scientist from Berghem, The Netherlands. Laurens spent his undergrad in Software Development (BSc, Avans Hogeschool ‘s-Hertogenbosch) and Computing Science (MSc, Radboud University Nijmegen). Laurens continued his career at a start-up, where he created large-scale, real-time analytical software. Laurens continued on his academic trajectory at the Radboudumc in Nijmegen, where he started his PhD in bioinformatics.

    During his PhD, Laurens integrated genetic data with protein 3D structures and protein domains. He utilized the skills he obtained before setting out on his academic trajectory; building large-scale, robust, reliable software. Exemplified by the MetaDome Web server ( During his PhD, he developed novel methodologies for the interpretation of genetic variants of unknown clinical significance and, by integrating structural and evolutionary biology with genomics, Laurens identified 36 novel disease-gene associations for developmental disorders. These discoveries enabled diagnosis for over 500 families worldwide.

    Laurens’ areas of expertise are (bioinformatic) software development, data integration of genetic variation with other omics, and his research aims are:
    1.) Lessons long-learned in computer science aid computational biology
    2.) Multi-omic data integration allows the impact measurement of genetic variation
    3.) Diagnosing undiagnosed disorders will uncover novel insights into biology.
    4.) International and multidisciplinary collaborations are key in diagnosing rare disorders.

    At Stanford University, under guidance of Dr. Matthew Wheeler, he is conducting his postdoctoral studies in line with his research aims.

  • Renu Verma

    Renu Verma

    Postdoctoral Scholar, Infectious Diseases

    BioMy research primarily focuses on clinical translational science of infectious diseases with an emphasis on tuberculosis and SARS-CoV-2. I leverage multiplex qPCR, whole genome sequencing and mass spectrometry-based technologies to develop novel diagnostics for pathogen detection and personalize TB treatment by pharmacogenomic analysis. In addition, I develop and test innovative approaches to study transmission of infectious diseases and evaluate control measures in congregate/community settings.

    Key Research:
    i)Development and validation of molecular viability assays for detection and quantification of novel SARS-CoV-2 virus in COVID-19 patients
    ii)Development and validation of a novel aerosol capture tool for the detection of SARS-CoV-2 in exhaled breath from COVID-19 patients with mild and severe symptoms
    iii)Development of a rapid pharmacogenomic assay to detect NAT2 polymorphisms and predict INH acetylation to guide dosing for tuberculosis treatment
    iv)Detection of M. tuberculosis in the environment as a novel tool for identifying high-risk locations for tuberculosis transmission
    v)Analyzing host serum biomarkers in latent and active Tuberculosis using ELISA assays in patients as a measure of disease severity.

  • Jorge Villalpando Salazar

    Jorge Villalpando Salazar

    Postdoctoral Medical Fellow, Pulmonary and Critical Care Medicine

    BioMy areas of interest include pulmonary vascular disease and lung transplantation. I feel passionate about this field of medicine because it allows me to practice very well-rounded medicine and implement all the knowledge acquired since the beginning of my residency training.

    As a lung transplant specialist, we follow our patients through this life changing journey and essentially become their primary care providers. I have the opportunity to practice hospital and pulmonary medicine in the wards managing end stage lung disease and other internal medicine pathologies. Lastly, we are a key component of the multidisciplinary team that takes care of the patient in the intensive care unit during the post operative period when our patients need us the most. The versatility of skill sets required to be a good lung transplant specialist keeps me on my toes and makes me love this profession.

    My ultimate career goal is to become an academic lung transplant specialist and contribute to this rapidly growing field. I am pursuing advanced training on lung transplantation at Stanford University Medical Center to help accomplish my dreams.

  • Brian Wayda

    Brian Wayda

    Postdoctoral Scholar, Cardiovascular Medicine
    Fellow in Medicine

    Current Research and Scholarly InterestsHeart transplant policy and outcomes, cost-effectiveness, mathematical modeling

  • Chad S. Weldy, M.D., Ph.D.

    Chad S. Weldy, M.D., Ph.D.

    Postdoctoral Medical Fellow, Cardiovascular Medicine
    Fellow in Medicine
    Resident in Medicine

    Current Research and Scholarly InterestsAs a physician-scientist in the lab of Dr. Quertermous I work to understand the genetic basis of cardiovascular disease and the transcriptional and epigenomic mechanisms of atherosclerosis. My work is focused across three main areas of cardiovascular genetics and mechanisms of coronary artery disease and smooth muscle biology:

    1.CRISPRi screening with targeted perturb seq (TAPseq) to identify novel CAD genes in human coronary artery smooth muscle cells
    2.Investigation of the epigenetic and molecular basis of coronary artery disease and smooth muscle cell transition in mice with conditional smooth muscle genetic deletion of CAD genes Pdgfd and Sox9
    3.Defining on single cell resolution the cellular and epigenomic features of human vascular disease across vascular beds of differing embryonic origin

    My work with Dr. Quertermous is focused on driving discovery in vascular biology by understanding how common genetic variation in humans in complex disease can lead to novel understandings of disease mechanism. With nearly 100,000 GWAS loci discovered across all complex disease, and nearly 300 GWAS loci identified within coronary artery disease, the methods by which GWAS loci are mapped to causal gene is often times limited based proximity to lead SNP without confirmatory functional genomic testing. By using CRISPRi screening in human coronary artery smooth muscle cells with targeted perturb seq (TAPseq), we aim to epigenetically modify specific GWAS loci to then understand enhancer-gene pairs and identify causal CAD genes within the region of a CAD GWAS loci. For identified CAD genes with high confidence for their causality, understanding how CAD genes modify smooth muscle cell state transition within the vascular wall and the epigenomic mechanisms by which this transition occurs is crucial. By using a vascular smooth muscle cell lineage traced mouse model, we can induce smooth muscle specific deletion of CAD genes, Pdgfd and Sox9 to better understand their causal mechanism in vascular disease with single cell RNAseq and single cell ATACseq. Understanding this cell state transition and epigenomic basis of disease is further expanded to human disease with collaboration from our cardiothoracic surgical colleagues. By harvesting human vascular samples at the time of transplant or organ donation, we have the unique ability to understand on a single cell resolution the mechanisms of vascular disease. Importantly, by comparing the cellular gene expression and cell population with scRNAseq in combination with understanding chromatin accessibility on single cell resolution with scATACseq across vascular beds from differing embryonic origin (coronary, ascending aorta, aortic arch, descending thoracic, infrarenal, carotid artery) we can work to understand why there is differential susceptibility to vascular disease across vascular sites and the epigenomic and transcriptional mechanisms that facilitate this differential susceptibility.

    This work attempts to apply multiple scientific research arms to ultimately lead to novel understandings of vascular disease and discover important new therapeutic approaches for drug discovery.